Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antibodies"" wg kryterium: Temat


Starter badań:

Tytuł :
Application of Single-Domain Antibodies ("Nanobodies") to Laboratory Diagnosis.
Autorzy :
Pillay TS; Department of Chemical Pathology and NHLS- Tshwane Academic Division, University of Pretoria, Pretoria, South Africa.; Division of Chemical Pathology, University of Cape Town, Cape Town, South Africa.; Department of Chemical Pathology, University of Pretoria, Prinshof Campus, Pretoria, South Africa.
Muyldermans S; Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.; Liaoning Key Laboratory of Molecular Recognition and Imaging, School of Bioengineering, Dalian University of Technology, Dalian, China.
Pokaż więcej
Źródło :
Annals of laboratory medicine [Ann Lab Med] 2021 Nov 01; Vol. 41 (6), pp. 549-558.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Single-Domain Antibodies*/genetics
Animals ; Antibodies, Monoclonal ; Camelus ; Clinical Laboratory Techniques ; Immunoglobulin Heavy Chains
Czasopismo naukowe
Tytuł :
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.
Autorzy :
Cho H; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Gonzales-Wartz KK; Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Huang D; Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.
Yuan M; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.
Peterson M; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Liang J; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Beutler N; Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.
Torres JL; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.
Cong Y; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Postnikova E; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Bangaru S; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.
Talana CA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Shi W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Yang ES; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Zhang Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Leung K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wang L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Peng L; Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.
Skinner J; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Li S; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Wu NC; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.
Liu H; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.
Dacon C; Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Moyer T; Flow Cytometry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Cohen M; Flow Cytometry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Zhao M; Protein Chemistry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Lee FE; Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University, Atlanta, GA 30322, USA.
Weinberg RS; New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY 10065, USA.
Douagi I; Flow Cytometry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Gross R; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Schmaljohn C; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Pegu A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Holbrook M; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Nemazee D; Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.
Rogers TF; Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.; Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
Ward AB; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.
Wilson IA; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.; Skaggs Institute for Chemical Biology, Scripps Research Institute, La Jolla, CA, 92037, USA.
Crompton PD; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Tan J; Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Pokaż więcej
Źródło :
Science translational medicine [Sci Transl Med] 2021 Oct 20; Vol. 13 (616), pp. eabj5413. Date of Electronic Publication: 2021 Oct 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Antibodies, Bispecific*/immunology
Spike Glycoprotein, Coronavirus/*immunology
Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; COVID-19 ; Humans ; SARS-CoV-2
SCR Organism :
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł :
Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1.
Autorzy :
Li S; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, China.
Qiao Y; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, China.
Jiang S; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, China.
Wang B; School of Chemistry and Life Science, Changchun University of Technology, Changchun, Jilin 130012, China.
Kong W; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, China; Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun, Jilin 130012, China.
Shan Y; National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, China; Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun, Jilin 130012, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2021 Oct 10; Vol. 338, pp. 633-643. Date of Electronic Publication: 2021 Sep 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Bispecific*
HIV Infections*/therapy
HIV-1*
Antibodies, Neutralizing ; HIV Antibodies ; Humans ; Immunization, Passive ; Neutralization Tests
Czasopismo naukowe
Tytuł :
Low immunogenicity of emicizumab in persons with haemophilia A.
Autorzy :
Schmitt C; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Emrich T; Roche Diagnostics GmbH, Penzberg, Germany.
Chebon S; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Fernandez E; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Petry C; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Yoneyama K; Chugai Pharmaceutical Co. Ltd, Tokyo, Japan.
Kiialainen A; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Howard M; Hoffmann-La Roche Ltd, Mississauga, Canada.
Niggli M; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Paz-Priel I; Genentech, Inc., South San Francisco, California, USA.
Chang T; Genentech, Inc., South San Francisco, California, USA.
Pokaż więcej
Źródło :
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Nov; Vol. 27 (6), pp. 984-992. Date of Electronic Publication: 2021 Sep 04.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Bispecific*/therapeutic use
Hemophilia A*/drug therapy
Antibodies, Monoclonal, Humanized/therapeutic use ; Factor VIII ; Humans
Czasopismo naukowe
Tytuł :
Role of configurational flexibility on the adsorption kinetics of bivalent bispecific antibodies on porous cation exchange resins.
Autorzy :
Kimerer LK; Department of Chemical Engineering, University of Virginia, Charlottesville, VA, USA.
Pabst TM; Purification Process Sciences, BioPharmaceuticals Development, AstraZeneca, Gaithersburg, MD, USA.
Hunter AK; Purification Process Sciences, BioPharmaceuticals Development, AstraZeneca, Gaithersburg, MD, USA.
Carta G; Department of Chemical Engineering, University of Virginia, Charlottesville, VA, USA. Electronic address: .
Pokaż więcej
Źródło :
Journal of chromatography. A [J Chromatogr A] 2021 Oct 11; Vol. 1655, pp. 462479. Date of Electronic Publication: 2021 Aug 20.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Bispecific*
Cation Exchange Resins*
Adsorption ; Antibodies, Monoclonal ; Chromatography, Ion Exchange ; Kinetics ; Porosity
Czasopismo naukowe
Tytuł :
Translational PK/PD and model-informed development of JNJ-67842125, a F ab reversal agent for JNJ-64179375, a long-acting thrombin inhibitor.
Autorzy :
Ayyar VS; Biologics Development Sciences, Janssen BioTherapeutics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Jaiprasart P; Biologics Development Sciences, Janssen BioTherapeutics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Geist B; Biologics Development Sciences, Janssen BioTherapeutics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Huang Devine Z; Cardiovascular and Metabolism, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Case M; New Platforms and Technology, Janssen BioTherapeutics, Janssen Research & Development, LLC, San Diego, California, USA.
Hazra A; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Hsu CH; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Chintala M; Cardiovascular and Metabolism, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Wang W; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Pokaż więcej
Źródło :
British journal of pharmacology [Br J Pharmacol] 2021 Oct; Vol. 178 (19), pp. 3943-3958. Date of Electronic Publication: 2021 Jun 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal*
Thrombin*
Animals ; Antibodies, Monoclonal, Humanized ; Blood Coagulation Tests ; Macaca fascicularis
Czasopismo naukowe
Tytuł :
Nanobodies - Little helpers unravelling intracellular signaling.
Autorzy :
Wagner TR; Pharmaceutical Biotechnology, Eberhard Karls University, Tübingen, Germany; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Rothbauer U; Pharmaceutical Biotechnology, Eberhard Karls University, Tübingen, Germany; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls University, Tübingen, Germany. Electronic address: .
Pokaż więcej
Źródło :
Free radical biology & medicine [Free Radic Biol Med] 2021 Nov 20; Vol. 176, pp. 46-61. Date of Electronic Publication: 2021 Sep 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Single-Domain Antibodies*
Antibodies ; Antigens
Czasopismo naukowe
Tytuł :
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
Autorzy :
Reuter U; Charité Universitätsmedizin Berlin, Berlin, Germany.
Lucas C; Hôpital Salengro, CHU de Lille, Lille, France.
Dolezil D; DADO MEDICAL, Prague, Czech Republic.
Hand AL; IQVIA, Durham, NC, 27703, USA.
Port MD; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Nichols RM; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Stroud C; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Tockhorn-Heidenreich A; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Detke HC; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. .
Pokaż więcej
Źródło :
Advances in therapy [Adv Ther] 2021 Nov; Vol. 38 (11), pp. 5465-5483. Date of Electronic Publication: 2021 Sep 20.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized*
Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal/therapeutic use ; Humans ; Middle Aged ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
Autorzy :
Janbain M; Hematology, Tulane School of Medicine, New Orleans, USA.
Enjolras N; UR4609 Hemostase & Thrombose, Universite Claude Bernard Lyon 1, Lyon, France.
Bolbos R; CERMEP, Centre d'Etude et de Recherche Multimodal Et Pluridisciplinaire, Lyon, France.
Brevet M; Cypath, Villeurbanne, France.
Bordet JC; UR4609 Hemostase & Thrombose, Universite Claude Bernard Lyon 1, Lyon, France.
Dargaud Y; UR4609 Hemostase & Thrombose, Universite Claude Bernard Lyon 1, Lyon, France.; Unite d'Haemostase Clinique, Centre d'Hemophilie, Hopital Cardiologique Louis Pradel, Lyon, France.
Pokaż więcej
Źródło :
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Nov; Vol. 27 (6), pp. 1002-1006. Date of Electronic Publication: 2021 Oct 13.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Bispecific*
Hemophilia A*/complications
Hemophilia A*/drug therapy
Hemostatics*
Tranexamic Acid*/therapeutic use
Animals ; Antibodies, Monoclonal, Humanized ; Factor VIII/therapeutic use ; Hemostasis ; Humans ; Mice
Czasopismo naukowe
Tytuł :
Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review.
Autorzy :
Donners AAMT; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, D.00.204, Postbus 85500, 3508 GA, Utrecht, The Netherlands. .
Rademaker CMA; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, D.00.204, Postbus 85500, 3508 GA, Utrecht, The Netherlands.
Bevers LAH; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, D.00.204, Postbus 85500, 3508 GA, Utrecht, The Netherlands.
Huitema ADR; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, D.00.204, Postbus 85500, 3508 GA, Utrecht, The Netherlands.; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Schutgens REG; Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Egberts TCG; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, D.00.204, Postbus 85500, 3508 GA, Utrecht, The Netherlands.; Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Fischer K; Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Pokaż więcej
Źródło :
Clinical pharmacokinetics [Clin Pharmacokinet] 2021 Nov; Vol. 60 (11), pp. 1395-1406. Date of Electronic Publication: 2021 Aug 13.
Typ publikacji :
Systematic Review
MeSH Terms :
Antibodies, Bispecific*
Hemophilia A*/drug therapy
Adolescent ; Adult ; Antibodies, Monoclonal, Humanized ; Child ; Factor VIII ; Humans
Tytuł :
Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.
Autorzy :
Yonemura S; Terumo Blood and Cell Technologies, Lakewood, CO, USA.
Hartson L; Infectious Disease Research Center, Colorado State University, Fort Collins, CO, USA.
Dutt TS; Department of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, CO, USA.
Henao-Tamayo M; Department of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, CO, USA.
Goodrich R; Infectious Disease Research Center, Colorado State University, Fort Collins, CO, USA.
Marschner S; Terumo Blood and Cell Technologies, Lakewood, CO, USA.
Pokaż więcej
Źródło :
Vox sanguinis [Vox Sang] 2021 Nov; Vol. 116 (10), pp. 1076-1083. Date of Electronic Publication: 2021 Apr 09.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Neutralizing*
COVID-19*/therapy
Antibodies, Viral ; Humans ; Immunization, Passive ; Riboflavin ; SARS-CoV-2 ; Technology ; Ultraviolet Rays
SCR Protocol :
COVID-19 serotherapy
Czasopismo naukowe
Tytuł :
Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors.
Autorzy :
Hassan E; Department of Paediatrics, NHS Foundation Trust, Paediatric Haematology, Haematology and Oncology Unit, Birmingham Children's Hospital, Birmingham, UK.
Jonathan L; Department of Paediatric Haematology, NHS Foundation Trust, Birmingham Children's Hospital, Birmingham, UK.
Jayashree M; Department of Paediatric Haematology, NHS Foundation Trust, Birmingham Children's Hospital, Birmingham, UK.
Pokaż więcej
Źródło :
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Nov; Vol. 27 (6), pp. e698-e703. Date of Electronic Publication: 2021 Oct 10.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Bispecific*
Hemophilia A*/drug therapy
Antibodies, Monoclonal, Humanized/therapeutic use ; Child ; Factor VIII/antagonists & inhibitors ; Hemorrhage/etiology ; Hemorrhage/prevention & control ; Humans
Czasopismo naukowe
Tytuł :
Not All Monoclonal Antibodies for Coronavirus Disease 2019 Are Created Equal.
Autorzy :
Stosor V; Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.; Division Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Angarone MP; Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Pokaż więcej
Źródło :
The Journal of infectious diseases [J Infect Dis] 2021 Oct 28; Vol. 224 (8), pp. 1275-1277.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Antibodies, Monoclonal*
COVID-19*
Antibodies, Viral ; Humans ; SARS-CoV-2
Opinia redakcyjna
Tytuł :
Efficacy and safety profile of avelumab monotherapy.
Autorzy :
Zhao B; The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, 325027, China. Electronic address: .
Gao M; The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, 325027, China.
Zhao H; The Cancer Center of the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519001, China.
Zhao J; Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, 519001, China.
Shen X; The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, 325027, China. Electronic address: .
Pokaż więcej
Źródło :
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2021 Oct; Vol. 166, pp. 103464. Date of Electronic Publication: 2021 Aug 28.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibodies, Monoclonal*/adverse effects
B7-H1 Antigen*
Antibodies, Monoclonal, Humanized/adverse effects ; Antibody-Dependent Cell Cytotoxicity ; Humans
Czasopismo naukowe
Tytuł :
Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.
Autorzy :
Salviani C; Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy .
Scolari F; Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy.; Department of Medical and Surgical Specialties, University of Brescia, Brescia, Italy.
Alberici F; Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy.; Department of Medical and Surgical Specialties, University of Brescia, Brescia, Italy.
Pokaż więcej
Źródło :
Annals of the rheumatic diseases [Ann Rheum Dis] 2021 Oct; Vol. 80 (10), pp. e158. Date of Electronic Publication: 2021 May 28.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antibodies, Neutralizing*
COVID-19 Vaccines*
Antibodies, Viral ; Humans ; Immunosuppression ; RNA, Messenger
Opinia redakcyjna
Tytuł :
Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection.
Autorzy :
Wisnivesky JP; Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. .; Division Pulmonary and Critical Care Medicine, Icahn School of Medicine at Mount Sinai, NY, New York, USA. .
Stone K; Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Bagiella E; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Doernberg M; Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Mendu DR; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lin JJ; Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Kale M; Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Pokaż więcej
Źródło :
Journal of general internal medicine [J Gen Intern Med] 2021 Oct; Vol. 36 (10), pp. 3289-3291. Date of Electronic Publication: 2021 Aug 03.
Typ publikacji :
Letter
MeSH Terms :
Antibodies, Neutralizing*
COVID-19*
Antibodies, Viral ; Humans ; SARS-CoV-2
Opinia redakcyjna
Tytuł :
The dynamic change of antibody index against Covid-19 is a powerful diagnostic tool for the early phase of the infection and salvage PCR assay errors.
Autorzy :
Omata M; Genome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan; The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. Electronic address: .
Hirotsu Y; Genome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Sugiura H; Division of Clinical Biochemistry and Immunology, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Maejima M; Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Nagakubo Y; Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan; Division of Genetics and Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Amemiya K; Division of Genetics and Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Hayakawa M; Central Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Tsutsui T; Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Kakizaki Y; Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Mochizuki H; Genome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan; Central Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan; Department of Gastroenterology, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Miyashita Y; Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Pokaż więcej
Źródło :
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi [J Microbiol Immunol Infect] 2021 Oct; Vol. 54 (5), pp. 830-838. Date of Electronic Publication: 2021 Jan 05.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Viral*
Diagnostic Errors*
COVID-19/*diagnosis
COVID-19/*immunology
COVID-19 Serological Testing/*methods
Polymerase Chain Reaction/*methods
SARS-CoV-2/*isolation & purification
Adult ; Africa ; Aged ; Aged, 80 and over ; Antibodies ; COVID-19 Testing/methods ; Disease Outbreaks ; Early Diagnosis ; Female ; Humans ; Japan ; Male ; Middle Aged ; Ships ; Young Adult
Czasopismo naukowe
Tytuł :
[Development of a blocking ELISA based on a single-domain antibody target the S1 protein of porcine epidemic diarrhea virus].
Autorzy :
Ma Z; College of Veterinary Medicine, Northwest Agricultural and Forestry University, Yangling 712100, Shaanxi, China.
Bai G; Weinan Animal Disease Control Center, Weinan 714000, Shaanxi, China.
Wang T; College of Veterinary Medicine, Northwest Agricultural and Forestry University, Yangling 712100, Shaanxi, China.
Li Z; College of Veterinary Medicine, Northwest Agricultural and Forestry University, Yangling 712100, Shaanxi, China.
Li Y; College of Veterinary Medicine, Northwest Agricultural and Forestry University, Yangling 712100, Shaanxi, China.
Xiao S; College of Veterinary Medicine, Northwest Agricultural and Forestry University, Yangling 712100, Shaanxi, China.
Li S; College of Veterinary Medicine, Northwest Agricultural and Forestry University, Yangling 712100, Shaanxi, China.
Pokaż więcej
Źródło :
Sheng wu gong cheng xue bao = Chinese journal of biotechnology [Sheng Wu Gong Cheng Xue Bao] 2021 Sep 25; Vol. 37 (9), pp. 3221-3230.
Typ publikacji :
Journal Article
MeSH Terms :
Coronavirus Infections*/veterinary
Porcine epidemic diarrhea virus*/genetics
Single-Domain Antibodies*
Swine Diseases*
Animals ; Antibodies, Viral ; Enzyme-Linked Immunosorbent Assay ; Reproducibility of Results ; Sensitivity and Specificity ; Swine
Czasopismo naukowe
Tytuł :
SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
Autorzy :
Law JLM; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada. Electronic address: .
Logan M; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Joyce MA; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Landi A; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Hockman D; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Crawford K; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Johnson J; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
LaChance G; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Saffran HA; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Shields J; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Hobart E; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Brassard R; Department of Biochemistry, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Arutyunova E; Department of Biochemistry, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Pabbaraju K; Alberta Precision Laboratories, Edmonton, Canada.
Croxen M; Alberta Precision Laboratories, Edmonton, Canada.
Tipples G; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada; Alberta Precision Laboratories, Edmonton, Canada.
Lemieux MJ; Department of Biochemistry, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Tyrrell DL; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
Houghton M; Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada. Electronic address: .
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Sep 24; Vol. 39 (40), pp. 5769-5779. Date of Electronic Publication: 2021 Aug 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Neutralizing*
COVID-19*
Antibodies, Viral ; Humans ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/genetics
SCR Organism :
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł :
Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection.
Autorzy :
Choe PG; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kang CK; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim KH; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea.
Yi J; Department of Laboratory Medicine, Pusan National University School of Medicine, Busan, Republic of Korea.
Kim ES; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Park SW; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim NJ; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Park WB; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Oh MD; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
The Journal of infectious diseases [J Infect Dis] 2021 Sep 17; Vol. 224 (6), pp. 1097-1099.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Antibodies, Neutralizing*
COVID-19*
Antibodies, Viral ; Antibody Formation ; Humans ; SARS-CoV-2
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies